Impact of postprocedure minimum stent area on long-term results following abciximab-coated stent implantation: An intravascular ultrasound analysis

International Journal of Cardiology

Volumn 123, Issue 1, 2007, Pages 23-28

  Hong, Young Joon ^a   Jeong, Myung Ho ^a   Hwang, Sun Ho ^a   Yun, Nam Sik ^a   Lim, Sang Yup ^a   Lee, Sang Rok ^a   Hong, Seo Na ^a   Kim, Kye Hun ^a   Park, Hyung Wook ^a   Kim, Ju Han ^a   Kim, Weon ^a   Ahn, Young Keun ^a   Cho, Jeong Gwan ^a   Park, Jong Chun ^a   Kang, Jung Chaee ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Coronary artery diseases; Intravascular ultrasound; Platelets; Stents

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; IMPLANTATION; INCIDENCE; INTRAVASCULAR ULTRASOUND; LOADING DRUG DOSE; MATERIAL COATING; MEASUREMENT; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVASCULARIZATION; STENT;

ANTIBODIES, MONOCLONAL; BLOOD VESSEL PROSTHESIS IMPLANTATION; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; STENTS; TIME FACTORS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 36148977184     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.11.101     Document Type: Article

References (28)

1. Hong Y.J., Jeong M.H., Kim W., et al. Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries. Am J Cardiol 94 (2004) 1050-1054
2. Morice M.C., Serruys P.W., Sousa J.E., et al., RAVEL Study Group. Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
3. Moses J.W., Leon M.B., Popma J.J., et al., SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
4. Schofer J., Schluter M., Gershlick A.H., et al., E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362 (2003) 1093-1099
5. Kuntz R.E., Safian R.D., Carrozza J.P., Fishman R.F., Mansour M., and Baim D.S. The importance of acute luminal diameter in determining restenosis after coronary atherectomy or stenting. Circulation 86 (1992) 1827-1835
6. Kuntz R.E., Gibson C.M., Nobuyoshi M., and Baim D.S. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J Am Coll Cardiol 21 (1993) 15-25
7. Sonoda S., Morino Y., Ako J., et al., SIRIUS Investigators. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the sirius trial. J Am Coll Cardiol 43 (2004) 1959-1963
8. Cheneau E., Pichard A.D., Satler L.F., Suddath W.O., Weissman N.J., and Waksman R. Intravascular ultrasound stent area of sirolimus-eluting stents and its impact on late outcome. Am J Cardiol 95 (2005) 1240-1242
9. Takebayshi H., Kobayashi Y., Mintz G.S., et al. Intravascular ultrasound assessment of lesions with target vessel failure after sirolimus-eluting stent implantation. Am J Cardiol 95 (2005) 498-502
10. Lakovou I., Mintz G.S., Dangas G., et al. Optimal final lumen area and predictors of target lesion revascularization after stent implantation in small coronary arteries. Am J Cardiol 92 (2003) 1171-1176
11. Kozuma K., Costa M.A., Sabate M., et al. Late stent malapposition occurring after intracoronary beta-irradiation detected by intravascular ultrasound. J Invas Cardiol 11 (1999) 651-655
12. Serruys P.W., Degertekin M., Tanabe K., et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 106 (2002) 798-803
13. Shah V.M., Mintz G.S., Apple S., and Weissman N.J. Background incidence of late malapposition after bare-metal stent implantation. Circulation 106 (2002) 1753-1755
14. Mintz G.S., Weissman N.J., and Pitzgerald P.J. Intravascular ultrasound assessment of the mechanisms and results of brachytherapy. Circulation 104 (2001) 1320-1325
15. Hong M.K., Mintz G.S., Lee C.W., et al. Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation. Circulation 109 (2004) 881-886
16. Tanabe K., Serruys P.W., Degertekin M., et al., TAXUS II Study Group. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insight from the randomized TAXUS II Trial. Circulation 111 (2005) 900-905
17. Ako J., Morino Y., Honda Y., et al. Late incomplete stent appostion after sirolimus-eluting stent implantation. J Am Coll Cardiol 46 (2005) 1002-1005
18. Hong M.K., Mintz G.S., Lee C.W., et al. Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation 113 (2006) 414-419
19. Uren N.G., Schwarzacher S.P., Metz J.A., et al. Predictors and outcomes of stent thrombosis: an intravascular ultrasound registry. Eur Heart J 23 (2002) 124-132
20. EPIC (Evaluation of 7E3 in Preventing Ischemic Complications) Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330 (1994) 956-961
21. EPILOG (Evaluation in PTCA to improve Long-Term outcome GP IIb/IIIa Blockade Study Group) Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336 (1997) 1689-1696
22. CAPTURE (C7E3 Fab AntiPlatelet Therapy in Unstable Refractory angina) Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet 349 (1997) 1429-1435
23. Platelet Receptor Inhibition in ischemic Syndrome Management in Patients Limited by Unstable Sings and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 338 (1998) 1488-1497
24. Reverter J.C., Beguin S., Kessels H., Kuman R., Hemker H.C., and Coller B.S. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 Fab treatment of an acute thrombosis and "clinical restenosis. J Clin Invest 98 (1996) 863-874
25. Shappel S.B., Toman C., Anderson D.C., Taylor A.A., Entman M.L., and Smith C.W. Mac-1 (CD11b/CD8) mediates adherence-dependent hydrogen peroxide production by human and canine neutrophils. J Immunol 144 (1990) 2702-2711
26. Simon D.I., Xu H., Ortelpp S., Rogers C., and Rao N.K. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Thromb Vasc Biol 17 (1997) 528-535
27. Mickelson J.K., Ali M.N., Kleiman N.S., Lakkis N.M., Chow T.W., and Hughes B.J. Chimeric 7E3 Fab (ReoPro) decreases detectable CD IIb on neutrophils from patients undergoing coronary angioplasty. J Am Coll Cardiol 33 (1999) 97-106
28. Lefkovits J., and Topol E.J. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Eur Heart J 17 (1996) 9-18